Breaking News Instant updates and real-time market news.

ANAB

AnaptysBio

$78.32

3.15 (4.19%)

06:58
08/07/18
08/07
06:58
08/07/18
06:58

AnaptysBio expects to report Phase 2a asthma data in Q3

AnaptysBio expects to report top-line efficacy and safety data, including improvement in Forced Expiratory Volume in One Second, from its ongoing double-blinded, placebo-controlled severe eosinophilic asthma trial Phase 2a trial, where approximately 24 adult severe eosinophilic asthma patients are treated with a 300mg intravenous single dose of etokimab versus placebo, each in combination with inhaled corticosteroids and long-acting beta agonists as background therapy, in Q3. Further, the company is enrolling a Phase 2b randomized, double-blinded, placebo-controlled, multi-dose study in 300 adult patients with moderate-to-severe atopic dermatitis, also referred to as the ATLAS clinical trial, to assess different dose levels and dosing frequencies of subcutaneously-administered etokimab for a 16-week treatment period followed by an eight-week follow-up period, with data expected in the second half of 2019.

  • 14

    Aug

ANAB AnaptysBio
$78.32

3.15 (4.19%)

04/04/18
RBCM
04/04/18
DOWNGRADE
Target $86
RBCM
Sector Perform
AnaptysBio downgraded to Sector Perform at RBC Capital on ANB020 uncertainty
As reported earlier, RBC Capital analyst Kennen MacKay downgraded AnaptysBio to Sector Perform from Outperform and lowered his price target to $86 from $144. MacKay cites "increasing skepticism regarding ANB020's path forward in peanut allergy" as post-data credibility concerns create an unfavorable risk-reward going into the company's phase 2a asthma readout expected in Q3. While the analyst expects the ANB020 readout to show a benefit vs. placebo, the results may be "challenging to interpret" relative to the treatment's competition.
05/29/18
JMPS
05/29/18
NO CHANGE
JMPS
JMP says AnaptysBio weakness ahead of asthma read-out a buying opportunity
After Aimmune Therapeutics (AIMT) presented new results from its Phase 3 trial of AR101 in peanut allergy at a medical congress, JMP Securities analyst Konstantinos Aprilakis noted that shares of competitor AnaptysBio (ANAB) are off about 42% over the last three months. He remains a buyer of AnaptysBio on any weakness going into the top-line proof of concept data from the Phase 2a trial of ANB020 in eosinophilic asthma, which is expected in Q3. The analyst, who reminds investors that he assigns about $61/share for the eosinophilic asthma indication in his valuation of AnaptysBio, maintains an Outperform rating and $180 price target on AnaptysBio shares, which closed Friday at $77.90.
07/09/18
JEFF
07/09/18
NO CHANGE
Target $145
JEFF
Buy
AnaptysBio can rally up to $30 on upcoming asthma data, says Jefferies
Jefferies analyst Biren Amin previews this quarter's readout of AnaptysBio's Phase IIa study testing ANB020 in severe asthma. The analyst's analysis suggests most biologics deliver 6%-9% improvement in lung function. A 7%-8% improvement likely drives $15-$20 of share upside while 9%-10% likely pushes the stock up $25-$30, Amin tells investors in a research note. He believes a the lower range of a 5%-6% improvement could trigger a selloff of $10-$15 per share and a true miss of less than 5% improvement could see the stock down $20-$25. He keeps a Buy rating on AnaptysBio with a $145 price target.
07/19/18
FBCO
07/19/18
INITIATION
Target $104
FBCO
Outperform
AnaptysBio initiated with an Outperform at Credit Suisse
Credit Suisse initiated AnaptysBio with an Outperform and $104 price target.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
08/15/18
08/15
12:17
08/15/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
08/15/18
08/15
12:16
08/15/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.78

-3.02 (-1.06%)

12:11
08/15/18
08/15
12:11
08/15/18
12:11
Technical Analysis
Technical Take: SPDR S&P 500 ETF off lows at midday »

The SPDR S&P 500 ETF…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.78

-3.02 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$22.53

-0.635 (-2.74%)

12:10
08/15/18
08/15
12:10
08/15/18
12:10
Recommendations
Vodafone analyst commentary  »

Vodafone added as a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$335.00

-12.6 (-3.62%)

12:10
08/15/18
08/15
12:10
08/15/18
12:10
Recommendations
Tesla analyst commentary  »

Tesla moved to Not Rated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

LB

L Brands

$31.63

-1.1 (-3.36%)

12:10
08/15/18
08/15
12:10
08/15/18
12:10
Options
Bullish longer-term option play in L Brands ahead of earnings next week »

Bullish longer-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

AMP

Ameriprise

$137.45

-1.23 (-0.89%)

12:10
08/15/18
08/15
12:10
08/15/18
12:10
Hot Stocks
Ameriprise to pay $4.5M for not safeguarding client assets »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHN

Schnitzer Steel

$25.95

-2.3 (-8.14%)

12:09
08/15/18
08/15
12:09
08/15/18
12:09
Conference/Events
Schnitzer Steel management to meet with KeyBanc »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 22

    Aug

TSLA

Tesla

$334.50

-13.1 (-3.77%)

, GS

Goldman Sachs

$229.91

0.38 (0.17%)

12:08
08/15/18
08/15
12:08
08/15/18
12:08
Periodicals
Breaking Periodicals news story on Tesla, Goldman Sachs »

Goldman Sachs to act as…

TSLA

Tesla

$334.50

-13.1 (-3.77%)

GS

Goldman Sachs

$229.91

0.38 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

CRC

California Resources

$28.77

-3.32 (-10.35%)

12:05
08/15/18
08/15
12:05
08/15/18
12:05
Options
California Resources call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

TSLA

Tesla

$334.80

-12.8 (-3.68%)

12:04
08/15/18
08/15
12:04
08/15/18
12:04
Periodicals
Silver Lake would like to participate in Tesla deal, DealBook says »

Silver Lake, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

ATVI

Activision Blizzard

$68.98

-2.31 (-3.24%)

, SNE

Sony

$53.46

-0.83 (-1.53%)

12:02
08/15/18
08/15
12:02
08/15/18
12:02
Hot Stocks
Activision's Call of Duty World League Championship comes to Ohio this week »

Activision Blizzard…

ATVI

Activision Blizzard

$68.98

-2.31 (-3.24%)

SNE

Sony

$53.46

-0.83 (-1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Sep

  • 13

    Sep

PFGC

Performance Food Group

$33.30

-4.3 (-11.44%)

12:00
08/15/18
08/15
12:00
08/15/18
12:00
Hot Stocks
Performance Food Group falls -11.4% »

Performance Food Group is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

CANG

Cango

$8.90

-1.6 (-15.24%)

12:00
08/15/18
08/15
12:00
08/15/18
12:00
Hot Stocks
Cango falls -12.0% »

Cango is down -12.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$36.24

-5.63 (-13.45%)

12:00
08/15/18
08/15
12:00
08/15/18
12:00
Hot Stocks
Macy's falls -13.4% »

Macy's is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 17

    Sep

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$10.22

1.31 (14.70%)

12:00
08/15/18
08/15
12:00
08/15/18
12:00
Hot Stocks
ProShares Trust Ultra VIX Short Term Futures ETF rises 14.6% »

ProShares Trust Ultra VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMG

KMG Chemicals

$77.39

10.61 (15.89%)

12:00
08/15/18
08/15
12:00
08/15/18
12:00
Hot Stocks
KMG Chemicals rises 15.7% »

KMG Chemicals is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$30.29

5.67 (23.03%)

12:00
08/15/18
08/15
12:00
08/15/18
12:00
Hot Stocks
Canopy Growth rises 22.9% »

Canopy Growth is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

12:00
08/15/18
08/15
12:00
08/15/18
12:00
General news
Short-covering on the S&P 500 ahead of 2.8k »

Short-covering on the…

M

Macy's

$36.27

-5.6 (-13.37%)

, STZ

Constellation Brands, also tag STZ.B

$202.15

-19.62 (-8.85%)

11:57
08/15/18
08/15
11:57
08/15/18
11:57
General news
Fly Intel: Wall Street's top stories at midday »

Stocks opened deep in…

M

Macy's

$36.27

-5.6 (-13.37%)

STZ

Constellation Brands, also tag STZ.B

$202.15

-19.62 (-8.85%)

CGC

Canopy Growth

$30.21

5.59 (22.71%)

KMG

KMG Chemicals

$77.30

10.52 (15.75%)

CCMP

Cabot Microelectronics

$111.65

-9.67 (-7.97%)

PETQ

PetIQ

$34.99

6.73 (23.81%)

FANG

Diamondback Energy

$120.33

-13.42 (-10.03%)

EGN

Energen

$76.24

3.09 (4.22%)

CASA

Casa Systems

$12.20

-3.425 (-21.93%)

STZ.B

Constellation Brands

$212.44

-8.54 (-3.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 15

    Aug

  • 15

    Aug

  • 21

    Aug

  • 22

    Aug

  • 11

    Sep

  • 17

    Sep

  • 25

    Oct

  • 28

    Oct

APC

Anadarko

$64.41

-2.56 (-3.82%)

11:55
08/15/18
08/15
11:55
08/15/18
11:55
Options
Anadarko put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRVS

Corvus Pharmaceuticals

$9.47

0.44 (4.87%)

11:55
08/15/18
08/15
11:55
08/15/18
11:55
Upgrade
Corvus Pharmaceuticals rating change  »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXS

BancorpSouth

$34.20

-0.2 (-0.58%)

11:45
08/15/18
08/15
11:45
08/15/18
11:45
Conference/Events
BancorpSouth management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 23

    Aug

BXS

BancorpSouth

$34.20

-0.2 (-0.58%)

11:45
08/15/18
08/15
11:45
08/15/18
11:45
Conference/Events
BancorpSouth management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 23

    Aug

ALRM

Alarm.com

$50.63

0.02 (0.04%)

11:43
08/15/18
08/15
11:43
08/15/18
11:43
Conference/Events
Alarm.com management to meet with Maxim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 22

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.